Pharma BD Deal Intelligence

Endo Pharmaceuticals Inc. / Algos Pharmaceutical Corporation

2000 · Acquisition/Merger · $250M · Complete

Skeptical — critic reaction at announcement

CALLED IT — OFF BY 6

Endo completed a $250M stock-swap acquisition of Algos Pharmaceutical (originally announced Nov 1999, repriced and closed Jul 17, 2000). Brought MorphiDex pain combination. The deal also took Endo public (Nasdaq: ENDP). MorphiDex later failed Phase 3 in 2002.

Did it work? Outcome assessment

Strategic verdict

Failed to Achieve

Financial impact

Impaired/Written Down

Pipeline outcome

Assets Terminated

Assessment window: 5yr post-close.

Key facts

Announced Jul 17, 2000
Closed Jul 17, 2000
Deal value $250M
Deal type Acquisition/Merger
Therapeutic area Oncology
Indications Moderate-to-severe cancer pain
Key assets MorphiDex (morphine + dextromethorphan)
Mechanism Mu-opioid agonist + NMDA receptor antagonist combination

Related deals — scored

Deal	Year	Value	Outcome
Endo Pharmaceuticals Inc. / Algos Pharmaceutical Corporation (this deal)	2000	$250M	34
Endo Pharmaceuticals Inc. / Indevus Pharmaceuticals, Inc.	2009	$370M	33
Endo Pharmaceuticals Inc. / SkyePharma plc	2003	$120M	17
Endo Pharmaceuticals Inc. / HealthTronics, Inc.	2010	$223M	17
Endo Pharmaceuticals Inc. / Qualitest Pharmaceuticals	2010	$1.2B	17
Endo Pharmaceuticals Inc. / American Medical Systems Holdings, Inc.	2011	$2.9B	13
Endo Pharmaceuticals Inc. / Penwest Pharmaceuticals Co.	2010	$144M	13

Compare all 7 side-by-side →

See the full interactive analysis, sources & comparables →

← Browse all deals · How we score deals

More: 2000 deals · Endo Pharmaceuticals Inc. deals · Oncology deals